{"id":48372,"date":"2024-08-12T14:25:33","date_gmt":"2024-08-12T14:25:33","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=48372"},"modified":"2024-08-12T14:26:31","modified_gmt":"2024-08-12T14:26:31","slug":"aids-2024-ten-early-reports","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/48372","title":{"rendered":"AIDS 2024: Ten early reports"},"content":{"rendered":"<h2><span><strong><a href=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2024\/07\/IAS-logo-for-web2.png\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-48051 alignright\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2024\/07\/IAS-logo-for-web2-219x300.png\" alt=\"\" width=\"185\" height=\"250\" \/><\/a><\/strong>Early reports from the conference will be added below as they are posted.<\/span><\/h2>\n<div>\n<ul>\n<li><a href=\"https:\/\/i-base.info\/htb\/48044\" rel=\"bookmark\">Research to watch out for at AIDS 2024<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/48260\" rel=\"bookmark\">Lenacapavir as PrEP is \u201cbeyond wonderful\u201d but PURPOSE 1 study tells us so much more\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/48224\" rel=\"bookmark\">Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/48358\" rel=\"bookmark\">Five days on two days off: Biktarvy in pilot FOTO study<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/48348\" rel=\"bookmark\">Sub-cutaneous formulation of long-acting CAB\/RPV discontinued<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/48128\" rel=\"bookmark\">New community call to challenge social settings that drive HIV-related stigma<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/48167\" rel=\"bookmark\">UNAIDS report: The urgency of now \u2013 AIDS at a crossroads.<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/48337\" rel=\"bookmark\">Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study<\/a><\/li>\n<\/ul>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Early reports from the conference will be added below as they are posted. Research to watch out for at AIDS 2024 Lenacapavir as PrEP is \u201cbeyond wonderful\u201d but PURPOSE 1 study tells us so much more\u00a0 Lenacapavir could be produced &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[335],"class_list":["post-48372","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-aids-25th-munich-2024"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/48372","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=48372"}],"version-history":[{"count":2,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/48372\/revisions"}],"predecessor-version":[{"id":48374,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/48372\/revisions\/48374"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=48372"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=48372"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=48372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}